The benefits of end-to-end formulation and fill-finish of biologics
Comprehensive mRNA Solutions
The M.O. Behind Choosing a CDMO: Three Considerations for New Drug Developers
A Year In Review — Curia’s (formerly AMRI) Contributions to Science in 2020
The Shift Toward US Pharmaceutical Manufacturing: Considerations in Attaining the Right Global Mix
COVID-19: Updates from AMRI
Selected AMRI Publications and Patents from 2005–2019
2019: A Year in Review — AMRI’s Contributions to Science